models the proteomic expression profile associated with exposure to Aurora and Polo-like
kinase inhibitors. The identification of proteomic expression patterns in patients with
NSCLC would be an important step in defining the possible role of these agents as potential
targeted therapies for this clinically important disease. This study proposes to evaluate
resected non-small cell lung cancer specimens for these proteomic expression profiles.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
- Cancer Help Line: (800) 639-6918
- Email: firstname.lastname@example.org
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.